8-K
filed February 25, 2025, 6:59 PM ET
ticker CBIO
CIK 0001253689
other material
confidence high
sentiment negative
materiality 0.85
GlycoMimetics loses China license for uproleselan; CEO, CFO, 5 directors depart
CRESCENT BIOPHARMA, INC.
- Apollomics terminated the collaboration license for uproleselan and GMI-1687 in China, effective 90 days from Feb 19, 2025.
- CEO Harout Semerjian and CFO Brian Hahn ceased employment on Feb 21, 2025; severance payments of $1,365,456 and $480,991 respectively.
- Five directors (Goldberg, Jackson, King, Koenig, Semerjian) resigned Feb 21, 2025; no disagreement with company operations.
- Semerjian consulting: $700/hr for 12 months; Hahn consulting: $15,000/month through change in control or Sep 30, 2025.
- Company is pursuing a merger with Crescent Biopharma (Form S-4 filed).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rachel King resigned as Director at CRESCENT BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Harout Semerjian resigned as Director at CRESCENT BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mark Goldberg resigned as Director at CRESCENT BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Jackson resigned as Director at CRESCENT BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brian Hahn departed as Chief Financial Officer at CRESCENT BIOPHARMA, INC..
- Action
- ceased employment
- Role
- Chief Financial Officer
Exact text from the filing
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Harout Semerjian departed as Chief Executive Officer at CRESCENT BIOPHARMA, INC..
- Action
- ceased employment
- Role
- Chief Executive Officer
Exact text from the filing
each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company’s Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Scott Koenig resigned as Director at CRESCENT BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
each of Mark Goldberg, M.D., Scott Jackson, Rachel King, and Scott Koenig, M.D., Ph.D. tendered their resignations from the Company’s Board of Directors, effective as of February 21, 2025.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.